NPM1 and acute myeloid leukemia: As expected, low CXCL12 expression patients showed significantly inferior survival probability in the FLT3-ITD absent (Fig. 5A, P = 0.003) and NPM1 mutated (Fig. 5B, P = 0.068, a trend for significance actually) patients, which could provide more subdivision proofs for AML based on the dichotomous stratification of CXCL12 expression.